Bio-Rad Laboratories (NYSE:BIO) Releases Earnings Results, Beats Estimates By $0.87 EPS

Bio-Rad Laboratories (NYSE:BIO) issued its earnings results on Tuesday. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.87, FiscalAI reports. The company had revenue of $651.00 million for the quarter, compared to analysts’ expectations of $623.99 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 8.59%.Bio-Rad Laboratories’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the business earned $2.61 EPS.

Here are the key takeaways from Bio-Rad Laboratories’ conference call:

• Q2 revenue was essentially flat at approximately $651 million, while currency-neutral sales declined 1.9% year over year. Clinical diagnostics returned to modest growth, but life sciences fell 5.1% on a currency-neutral basis due to academic-market weakness and a difficult process-chromatography comparison.
• Digital PCR remained a key growth driver, with currency-neutral revenue up 6% and instrument sales increasing more than 20%. Management cited broad-based competitive wins, the Stilla portfolio, and expected future consumables pull-through as support for mid-single-digit near-term growth and potentially high-single-digit growth over time.
• Management reaffirmed a cautious 2026 outlook, forecasting currency-neutral revenue growth of -3% to +0.5% and noting approximately $4 million of second-half headwinds from China, continued life-science softness, order timing, Middle East volatility, and elevated logistics costs.
• Bio-Rad announced organizational and footprint changes expected to generate $30 million-$35 million in annualized net savings, with most savings realized by the end of 2027 and an estimated 40-50 basis points of incremental operating-margin expansion in 2027. The company also highlighted AI-enabled productivity gains and continued investment in innovation.
• The company is maintaining its strategic flexibility around its Sartorius stake, describing it as a valuable and monetizable asset, while continuing constructive discussions with Elliott Management. Bio-Rad repurchased approximately $32 million of shares in Q2 and had $206 million remaining under its buyback authorization as of June 30.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO opened at $339.01 on Thursday. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12. The stock has a fifty day simple moving average of $301.88 and a two-hundred day simple moving average of $287.99. Bio-Rad Laboratories has a 1-year low of $236.73 and a 1-year high of $352.63. The firm has a market cap of $9.07 billion, a price-to-earnings ratio of 41.39 and a beta of 1.06.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Zacks Research lowered Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Royal Bank Of Canada upped their price target on Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an “outperform” rating in a report on Wednesday. Wells Fargo & Company increased their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research report on Wednesday. Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Monday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $343.33.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Royal Bank of Canada grew its position in shares of Bio-Rad Laboratories by 25.2% during the 1st quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock valued at $7,382,000 after purchasing an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Bio-Rad Laboratories by 45.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after purchasing an additional 32,874 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Bio-Rad Laboratories by 14.8% in the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after purchasing an additional 199 shares in the last quarter. Jane Street Group LLC increased its position in shares of Bio-Rad Laboratories by 95.3% during the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock valued at $9,105,000 after purchasing an additional 18,239 shares during the last quarter. Finally, Cetera Investment Advisers increased its position in shares of Bio-Rad Laboratories by 13.5% during the 2nd quarter. Cetera Investment Advisers now owns 2,192 shares of the medical research company’s stock valued at $529,000 after purchasing an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.